1982
DOI: 10.1111/j.1365-2141.1982.tb07287.x
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations

Abstract: Changes in the British Pharmacopoeia dissolution time requirements have necessitated reformulation of warfarin sodium ('Marevan'). The old and new formulations were compared with each other in eight healthy volunteers given a single 15 mg dose of each in a cross-over study and also in 19 patients receiving warfarin therapy. In the volunteer study, a significant but small increase in bioavailability was observed for the new formulation. However, the effects of the two formulations on the prothrombin ratio and o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

1989
1989
2017
2017

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(10 citation statements)
references
References 15 publications
0
10
0
Order By: Relevance
“…Food slightly decreases the rate but not the extent of absorption (Melander 1978); unchanged warfarin has not been recovered from stool (Aggeler & O'Reilly 1966). Using high performance liquid chromatography, peak plasma concentrations have been observed between 0.3 and 4 hours, but 1 study reports a secondary peak between 1 and 8 hours (Stirling et al 1982). …”
Section: Absorptionmentioning
confidence: 99%
“…Food slightly decreases the rate but not the extent of absorption (Melander 1978); unchanged warfarin has not been recovered from stool (Aggeler & O'Reilly 1966). Using high performance liquid chromatography, peak plasma concentrations have been observed between 0.3 and 4 hours, but 1 study reports a secondary peak between 1 and 8 hours (Stirling et al 1982). …”
Section: Absorptionmentioning
confidence: 99%
“…25 mg) in the absence or presence of steady-state treatment of the drug that has potential to interact with warfarin; the use of a higher single dose of warfarin allows greater potential to detect an interaction as well as reduces the exposure of healthy volunteers to a prolonged period of anticoagulation. In some published studies, the interaction of a drug with warfarin has been assessed by administration of a single lower (10-15 mg) oral dose of warfarin [13,14]. A 7% decrease in S-warfarin AUC could be demonstrated after a single 10-mg dose of warfarin.…”
Section: Introductionmentioning
confidence: 99%
“…In the initial phase of anticoagulation (i.e., the first weeks of therapy), the INR is exquisitely labile and its relationship to the plasma concentration of vitamin K-dependent coagulants is complex [9,10]. The risk of hemorrhage per 100 patient months is increased between 2-7 times in the first 3 months of therapy compared to patients on warfarin for greater than 1 year [6][7][8].…”
Section: Introductionmentioning
confidence: 99%
“…The risk of hemorrhage per 100 patient months is increased between 2-7 times in the first 3 months of therapy compared to patients on warfarin for greater than 1 year [6][7][8]. Several previous studies indicate that the plasma concentration of native (i.e., functionally carboxylated) prothrombin may be a more accurate indicator of the likelihood of thromboembolic and hemorrhagic complications associated with warfarin therapy [9][10][11][12][13]. Therefore, we measured the concentration of multiple fragments of prothrombin in both the plasma and the urine to evaluate potentially superior markers for the monitoring of warfarin anticoagulation.…”
Section: Introductionmentioning
confidence: 99%